Technical Data
E3455-07A
Erythropoietin, alpha, Recombinant, Human (Powder) (EPO, EPO-a, EPO-alpha, Epoetin, EP, MGC138142)
5ug
50ug
50ug
|
Technical Data |
|
E3455-07A |
Erythropoietin, alpha, Recombinant, Human (Powder) (EPO, EPO-a, EPO-alpha, Epoetin, EP, MGC138142) |
5ug 50ug |
| Growth Factors, Cytokines | Storage: -20°CShipping: Dry Ice |
|
This gene is a member of the EPO/TPO family and encodes a secreted, glycosylated cytokine composed of four alpha helical bundles. The protein is found in the plasma and regulates red cell production by promoting erythroid differentiation and initiating hemoglobin synthesis. This protein also has neuroprotective activity against a variety of potential brain injuries and antiapoptotic functions in several tissue types. Erythropoietin-alpha Human Recombinant is produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology is a single, polypeptide chain containing 165aa and having a predicted molecular mass of 21kD and apparent glycosylated molecular mass of 30.4kD. Specific Activity: Measured using Normocythaemic mice 120,000 IU/mg Storage and Stability: Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with ddH2O, 0.1% BSA or HSA, aliquot and store at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. Molecular Weight: 34-36kD |
Source: Recombinant Human in Chinese hamster ovary (CHO) cells Purity: Chromatographically purified. 98% by RP-HPLC, Anion-exchange FPLC. Analyzed by reducing and non-reducing SDS-PAGE, Silver Stained. Endotoxin: 0.1ng/ug (IEU/ug) Concentration: ~0.1mg/ml Form: Supplied as a lyophilized,powder from sodium citrate, sodium chloride, citric acid buffer. Reconstitute with sterile, ddH2O, 0.1% HSA or BSA. Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological. |
|
1. Ford PA, Ford JM, (2004) Transfusion Dec 44(12 Suppl):15S-25S. 2. Wei X, Swanson SJ, (2004) J Immunol Methods Oct 293(1-2):115-26. 3. Godin M, (2004) Soins Sep (688 Suppl):5. 4. Cervantes F, Alvarez-Larran A, Sureda A, (2004) Br J Haematol Nov 127(4):399-403. 5. Mesjasz J, Wiecek A, Mazur W, (2004) Pol Merkuriusz Lek Apr 16(94):362-7. 6. Bergstrom S, Ahlgren J, (2004) Lakartidningen Oct 7 101(41):3160-1.
|
||